Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) notes an article published in the Australian newspaper, which stated “Neuren Pharmaceuticals is understood to have brought in a defence adviser after fielding buyer interest from US-based industry giants”. Neuren appointed a corporate and strategic adviser several months ago. The appointment was a normal step in Neuren’s ongoing growth and development and not in response to any approaches from third parties. Media speculation to the contrary is unfounded.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.85 |
Change
-0.110(0.85%) |
Mkt cap ! $1.598B | |||
| Open | High | Low | Value | Volume |
| $12.82 | $13.05 | $12.53 | $6.559M | 511.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1657 | $12.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.85 | 6303 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |